Li 2006a.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: eight weeks. Design: parallel. Setting: inpatient and outpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more. N = 76. Age: aripiprazole group: 18～59 years. mean = (8. 6 ± 8. 7) years; risperidone group: 20～58 years, mean = (29. 8 ± 9. 3) years. Gender: aripiprazole group: 20 male, 18 female; risperidone group: 21 male, 17 female. History: aripiprazole group: 1 month～13 years, mean = 6.5 years; risperidone group: 2 months～12 years, mean = 7.2 years. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 10‐30 mg/day. Mean = (18.3 ± 4.2) mg/day. N=38. 2. Risperidone: Dose range: 1‐6 mg/day. Mean = (3.1 ± 1.2) mg/day. N=38.
Outcomes	Global state: PANSS score decreased rate (recovery: ≥ 75%, markedly improved: 50%‐75%, improved: 25%‐50%, no effect: < 25%). CGI score. Mental state: PANSS total score, PANSS positive subscale score, PANSS negative subscale score, PANSS psychopathological subscale score, anxiety‐ labelled as "adverse effect", excitement/agitation‐labelled as "adverse effect". Leaving the study early. Adverse effects.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	The total proportion of loss to follow‐up was 2.63% (1/38: 0/38), all because of adverse effects.
Selective reporting (reporting bias)	High risk	Data on TESS total score, blood and urine routine, renal function, use of benzodiazepines and anticholinergic drug were missing.
Other bias	Low risk	None obvious.